F-2, also known as 6-(2-aminopropyl)-5-methoxy-2-methyl-2,3-dihydrobenzofuran or as benzofuran-2-methyl-5-methoxy-6-(2-aminopropane), is a chemical compound and possible psychedelic drug of the phenethylamine, amphetamine, and benzofuran families. It is the derivative of 6-APDB with a methyl group at the 2 position and a methoxy group at the 5 position of the benzofuran ring system.
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists F-2's dose as greater than 15mg orally and its duration as unknown. The drug produced no effects at assessed doses of up to 15mg. Higher doses were not tested. It is unknown whether F-2 is active. On the other hand, David E. Nichols reported in 1981, via personal communication with Shulgin and M. Trampota in 1980, that F-2 was "shown to possess clinical activity".
F-2 has been found to substitute for the psychedelic drug DOM in drug discrimination tests in rats. However, it was about 40-fold less potent than DOM in this regard, requiring a dose of 5mg/kg. For comparison, F-2 was tested in humans at doses of only up to 0.2mg/kg. In contrast to the case of rats, F-2 at doses of up to 100mg/kg intraperitoneally in mice was without effects. A dose of 150mg/kg intraperitoneally in mice was lethal.
The chemical synthesis of F-2 has been described.
Analogues of F-2 include DOPR, 6-APDB, MMDA-2, F (F-1), and F-22, among others.
F-2 was first described in the scientific literature by David E. Nichols in 1981 via personal communication with Alexander Shulgin and M. Trampota in 1980. Subsequently, it was described in greater detail by Nichols and colleagues in 1986 and 1991 and by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991. Shulgin briefly alluded to F and its derivatives in a paper in 1971.
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.